AU2014360606A1 - Methods for the prognosis of breast cancer - Google Patents

Methods for the prognosis of breast cancer

Info

Publication number
AU2014360606A1
AU2014360606A1 AU2014360606A AU2014360606A AU2014360606A1 AU 2014360606 A1 AU2014360606 A1 AU 2014360606A1 AU 2014360606 A AU2014360606 A AU 2014360606A AU 2014360606 A AU2014360606 A AU 2014360606A AU 2014360606 A1 AU2014360606 A1 AU 2014360606A1
Authority
AU
Australia
Prior art keywords
icd
nuclear
breast cancer
score
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014360606A
Other languages
English (en)
Inventor
Ranju Ralhan
Paul Walfish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/099,529 external-priority patent/US20140187438A1/en
Priority claimed from US14/501,020 external-priority patent/US20150094224A1/en
Application filed by Individual filed Critical Individual
Publication of AU2014360606A1 publication Critical patent/AU2014360606A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2014360606A 2013-12-06 2014-12-05 Methods for the prognosis of breast cancer Abandoned AU2014360606A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/099,529 US20140187438A1 (en) 2010-05-04 2013-12-06 Methods and Compositions for the Diagnosis and Treatment of Epithelial Cancers
US14/099,529 2013-12-06
US14/501,020 2014-09-29
US14/501,020 US20150094224A1 (en) 2010-05-04 2014-09-29 Methods for the diagnosis or prognosis of breast cancer
PCT/CA2014/051176 WO2015081446A1 (en) 2013-12-06 2014-12-05 Methods for the prognosis of breast cancer

Publications (1)

Publication Number Publication Date
AU2014360606A1 true AU2014360606A1 (en) 2016-07-21

Family

ID=53272695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014360606A Abandoned AU2014360606A1 (en) 2013-12-06 2014-12-05 Methods for the prognosis of breast cancer

Country Status (5)

Country Link
EP (1) EP3077812A4 (enExample)
JP (1) JP2017500590A (enExample)
AU (1) AU2014360606A1 (enExample)
CA (1) CA2932846A1 (enExample)
WO (1) WO2015081446A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601505B2 (en) * 2003-05-29 2009-10-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20110097732A1 (en) * 2009-10-26 2011-04-28 Medinnova As Novel biomarker for the prognosis of breast cancer
WO2011137513A1 (en) * 2010-05-04 2011-11-10 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide

Also Published As

Publication number Publication date
JP2017500590A (ja) 2017-01-05
CA2932846A1 (en) 2015-06-11
WO2015081446A1 (en) 2015-06-11
EP3077812A4 (en) 2017-06-07
EP3077812A1 (en) 2016-10-12
WO2015081446A9 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
Ahn et al. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
Botti et al. Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma
EP2494351B1 (en) Colon and rectal tumor markers and methods of use thereof
US20120052071A1 (en) Tumor markers and methods of use thereof
US8377648B2 (en) Autoimmune regulation of prostate cancer by annexin A3
Aras et al. Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis
Ba et al. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis
Tsuna et al. Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma
JP2013543117A (ja) Ｂｒａｆｖ６００ｅに特異的に結合する抗体を使用する癌の診断のための手段及び方法
US20080166733A1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
EP2494361B2 (en) Ovary tumor markers and methods of use thereof
EP2707721A1 (en) Predictive biomarkers for prostate cancer
US20160313335A1 (en) Methods for the Prognosis of Breast Cancer
JP2012501440A (ja) 内分泌処置予測因子としてのａｎｌｎタンパク質
CN103180455B (zh) 侦测致死系统的方法及其用途
Nosaka et al. Cytoplasmic maspin expression correlates with poor prognosis of patients with adenocarcinoma of the uterine cervix
Srivastava et al. Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients
Madeira et al. Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer
EP2288721A1 (en) Treatment prediction involving hmgcr protei
JP2022153482A (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
AU2014360606A1 (en) Methods for the prognosis of breast cancer
WO2009139681A1 (en) Treatment prediction involving hmgcr protei
EP2269073B1 (en) A method of assessing cancer status in a breast cancer patient
WO2016106453A1 (en) Nuclear ep-icd as a prognosis marker for prostate cancer
US20140170135A1 (en) Egfr expression is associated with decreased benefit from trastuzumab in the ncctg n9831 trial

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period